Abstract | BACKGROUND: OBJECTIVE: To investigate levels of this biomarker in subjects with MCI. DESIGN AND MAIN OUTCOME MEASURES: Using gas chromatography-mass spectrometry analysis, we measured 8,12-iso-iPF(2alpha)-VI levels in urine, plasma, and cerebrospinal fluid of patients with AD, subjects with MCI, and cognitively normal elderly subjects. SETTING AND PATIENTS: RESULTS: We found significantly higher 8,12-iso-iPF(2alpha)-VI levels in cerebrospinal fluid, plasma, and urine of subjects with MCI compared with cognitively normal elderly subjects. CONCLUSIONS: These results imply that individuals with MCI have increased brain oxidative damage before the onset of symptomatic dementia. Measurement of this isoprostane may identify a subgroup of patients with MCI with increased lipid peroxidation who are at increased risk to progress to symptomatic AD.
|
Authors | Domenico Praticò, Christopher M Clark, Feyan Liun, Joshua Rokach, Virginia Y-M Lee, John Q Trojanowski |
Journal | Archives of neurology
(Arch Neurol)
Vol. 59
Issue 6
Pg. 972-6
(Jun 2002)
ISSN: 0003-9942 [Print] United States |
PMID | 12056933
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Alzheimer Disease
(diagnosis, metabolism, psychology)
- Analysis of Variance
- Brain
(metabolism)
- Cognition Disorders
(metabolism, psychology)
- Female
- Humans
- Lipid Peroxidation
(physiology)
- Male
- Middle Aged
- Oxidative Stress
(physiology)
- Predictive Value of Tests
|